MEDIROM Healthcare Technologies (MRM) has released an update.
MEDIROM Healthcare Technologies Inc. is set to acquire a 70% stake in Japan Gene Medicine Corporation, a company specializing in prenatal genetic testing and analysis, with an option to purchase the remaining shares. The deal is expected to bolster MEDIROM’s HealthTech portfolio and capitalize on the growing demand for genetic testing in Japan, where usage among pregnant women has been historically low. This strategic move aligns with MEDIROM’s goal to expand as a comprehensive healthcare service provider in the Japanese market.
For further insights into MRM stock, check out TipRanks’ Stock Analysis page.
